Limited Offer
Fibroblast Activation Protein Imaging, An Issue of PET Clinics
- 1st Edition, Volume 18-3 - June 1, 2023
- Editors: Frederik L. Giesel, Rodney Hicks, Ken Herrmann
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 3 8 9 5 - 2
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 3 8 9 6 - 9
In this issue, guest editors bring their considerable expertise to this important… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quote-
Contains 16 practice-oriented topics including fibroblast activation protein inhibitor (FAPI) PET imaging in pancreatic cancer; fibroblast activation protein inhibitor (FAPI) PET imaging in colorectal cancer; fibroblast activation protein inhibitor (FAPI) cardiac imaging; fibroblast activation protein inhibitor (FAPI) PET/CT in gastric cancer; and more.
-
Provides in-depth clinical reviews on fibroblast activation protein imaging, offering actionable insights for clinical practice.
-
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Forthcoming Issues
- CME Accreditation Page
- Preface
- Advanced Fibroblast Activation Protein-Ligand Developments: FAP Imaging Agents: A Review of the Structural Requirements
- Key points
- Introduction
- Rationale for fibroblast activation protein-α inhibitor design
- Improving retention
- Improving delivery
- Summary
- Clinics care points
- Disclosure
- Fibroblast Activation Protein Inhibitor PET in Pancreatic Cancer
- Key points
- Introduction
- Fibroblast activation protein inhibitor PET/computed tomography and PET/MR imaging in the diagnosis of pancreatic cancer
- Prognostic value of FAPI PET in pancreatic cancer
- Increased fibroblast activation protein inhibitor uptake in nonmalignant pancreatic lesions
- Summary
- Clinics care points
- Declaration of interests and source of funding
- The Diagnostic Value of Fibroblast Activation Protein Imaging in Hepatocellular Carcinoma and Cholangiocellular Carcinoma
- Key points
- Background
- The diagnostic value and limitations of the standard-of-care imaging with [18F]FDG PET/CT scan
- Cancer-associated fibroblast and its role in carcinogenesis of hepatocellular carcinoma and cholangiocellular carcinoma
- Fibroblast activation protein overexpression and Fibroblast activation protein ligands in PET imaging
- Current state of the research in fibroblast activation protein imaging
- Outlook
- Clinics care points
- Conflict of Interest
- Fibroblast Activation Protein Inhibitor PET Imaging in Head and Neck Cancer
- Key points
- Introduction: overview of head and neck cancers
- Normal anatomy and imaging technique
- Protocols
- Imaging findings/pathology
- Clinical applications
- Diagnostic criteria
- Differential diagnosis
- Case study presentation
- Clinics care points
- Declaration of Interests
- Fibroblast Activation Protein Inhibitor-PET Imaging in Colorectal Cancer
- Key points
- Introduction
- FAPI-PET imaging in colorectal cancer
- Summary
- Clinics care points
- Disclosure
- Fibroblast Activation Protein Inhibitor PET/CT in Gastric Cancer
- Key points
- Introduction
- Current status of [18F]fluorodeoxyglucose-PET imaging in gastric cancer
- Fibroblast activation protein expression in gastric cancer
- Clinical applications of fibroblast activation protein inhibitor-PET in gastric cancer
- Summary
- Clinics care points
- Funding
- Disclosure
- Current Status of Fibroblast Activation Protein Imaging in Gynecologic Malignancy and Breast Cancer
- Key points
- Introduction
- Summary
- Clinics care points
- Disclosures
- Fibroblast Activation Protein Inhibitor (FAPI)-PET Imaging in Sarcoma
- Key points
- Introduction
- Background
- Fibroblast activation protein
- Fibroblast activation protein and sarcoma
- 68Ga-FAPI from bench to bedside in patients with sarcoma
- PET imaging in sarcoma and impact of 68Ga-FAPI
- Limitations of current data and future perspectives
- Summary
- Clinics care points
- Disclosure
- Fibroblast Activation Protein Inhibitor Theranostics: The Case for Use in Sarcoma
- Key points
- Introduction
- Future directions
- Discussion
- Summary
- Clinics care points
- Declaration of Interests
- Radiation Therapy Planning Using Fibroblast Activation Protein Inhibitor
- Key points
- Introduction
- Standard imaging techniques for radiation oncology
- Clinical applications of fibroblast activation protein inhibitor for radiation oncology
- Discussion
- Summary
- Clinics care points
- Imaging Fibrosis
- Key points
- Introduction
- Discussion/emerging trends
- Retroperitoneal Fibrosis
- Using fibroblast activation protein inhibitor to select and monitor antifibrotic therapies
- Summary
- Clinics care points
- Disclosure
- Cardiac Applications of Fibroblast Activation Protein Imaging
- Key points
- Overview
- Fibroblast activation protein PET imaging versus established fibrosis-imaging tools
- Clinics care points
- Funding
- Disclosure
- Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Considerations
- Key points
- Introduction
- Preclinical Evaluation of Fibroblast Activation Protein Inhibitor in Animal Models
- Development of Fibroblast Activation Protein Inhibitor Chemicals
- Compound Structure and Biological Affinity
- Discussion in the future
- Summary
- Conflict of interest
- Disclosure
- Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Combination Treatment
- Key points
- Introduction
- Fibroblast activation protein radioligand therapy
- Leveraging responses to DNA damage
- Exploiting radioligand therapy-induced immunomodulation
- Radiation responses of cancer-associated fibroblasts and their potential utilization in combination therapy
- Co-targeting the tumor microenvironment
- Discussion and conclusion
- Disclosure
- Fibroblast Activation Protein Inhibitor Theranostics: Early Clinical Translation
- Key points
- Overview
- Early theranostic application of fibroblast activation protein inhibitor ligands
- Further development of theranostic tracer: FAPI-46
- Radioligand therapy with FAPI-46
- Recent theranostic agent developments
- Role of radiochemistry
- Future perspectives
- Author contribution
- Conflicts of interest
- Clinics care points
- Current State of Clinical Trials and Regulatory Approvals with Fibroblast Activation Protein Targeting Interventions
- Key points
- Background
- Current trials
- Future directions
- Summary
- Clinics care points
- Disclosure
- No. of pages: 240
- Language: English
- Edition: 1
- Volume: 18-3
- Published: June 1, 2023
- Imprint: Elsevier
- Hardback ISBN: 9780323938952
- eBook ISBN: 9780323938969